Why LIB Therapeutics’ lerodalcibep data matter for next-generation cholesterol care
Monthly PCSK9 therapy is getting crowded. LIB Therapeutics’ LEROCHOL data raise a sharper question on adherence, access and durability.
Can Merck’s enlicitide decanoate become the oral PCSK9 breakthrough cholesterol care has been waiting for?
Merck’s enlicitide decanoate beat oral rivals in Phase 3. Read what this could change for cholesterol care, PCSK9 adoption, and market strategy.